Scientific Program

Wednesday, 17. October 2018
07:15	Registration
08:00	Welcome
08:15	Session 1: Immunogenicity/Biomarker Chairs: Therasa L. Whiteside, Pittsburgh, USA \| Jochen Hess, Heidelberg, Germany Human leukocyte antigens and haplotypes allow for prognostic classification of HNSCC patients Gunnar Wichmann, Leipzig, Germany Breaking the brakes: Targeting immune suppressive cells Marco C. Merlano, Cuneo, Italy Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. Ezra Cohen, San Diego, USA Immunotherapy and Head and Neck Cancer : Focus on recurrent and metastatic disease Robert Haddad, Boston, USA
09:45	Coffee break / Industrial Exhibtion / Poster
10:15	Session 2: Liquid Biopsy Chairs: Marco C. Merlano, Cuneo, Italy \| Robert Haddad, Boston, USA Extracellular Vesicles as biomarkers for cancer progression and cancer associated VTE Frank Gieseler, Lübeck, Germany Immune modulation by extracellular vesicles released from mesenchymal cells Martina Seifert, Berlin, Germany Monitoring ctDNA in Liquid Biopsy for Cancer Therapy - Facts and Hopes Jochen Hess, Heidelberg, Germany The potential diagnostic/prognostic role of plasma-derived exosomes in HNSCC Therasa L. Whiteside, Pittsburgh, USA
11:45	Posters of the day Chair: Ezra Cohen, San Diego, USA Regulatory T cells in endogenous mouse lymphoma are antigen-specific nTregs and provide a target for immune checkpoint-inhibiting therapies (P14) Vera Bauer, Munich, Germany The role of NFATc1 in T cell-mediated immune responses during the development of lung cancer (P05) Lisanne Heim, Erlangen, Germany Activation of MDA5 improves anti-tumor therapy and reduces suppressive capacity of myeloid-derived suppressor cells (P11) Phillip Metzger, Munich, Germany
12:30	Industry Symposium with Snack MSD Sharp & Dohme GmbH SCCHN: Current state and future trends Chair: Viktor Grünwald, Germany R/M SCCHN - Today Tanguy Seiwert, USA R/M SCCHN - Tomorrow Viktor Grünwald, Germany R/M SCCHN - Soon? Andreas Dietz, Germany
13:30	Postersession All presenters are asked to be present at their poster.
14:15	Session 3: Cellular vaccines Chairs: Bernardo S. Franklin, Bonn, Germany \| Hans-Georg Rammensee, Tübingen, Germany CAR NK cells for cancer retargeting Ulrike Koehl, Leipzig, Germany Immune biological rationale for the design of radioimmunotherapies Udo Gaipl, Erlangen, Germany Role of resident memory T cells in cancer immunotherapy Eric Tartour, Paris, France Perspectives of gd T cells in cancer immunotherapy Dieter Kabelitz, Kiel, Germany
15:45	Coffee break / Industrial Exhibtion / Poster
16:15	Session 4: New targets I Chairs: Ulrike Koehl, Leipzig, Germany \| Eric Tartour, Paris, France On the development of personalized cancer vaccines Hans-Georg Rammensee, Tübingen, Germany Platelets regulate innate immunity in autoinflammtory diseases and cancer Bernardo S. Franklin, Bonn, Germany A Pan-cancer Landscape of Interactions between Tumors and infiltrating immune cells David Tamborero, Stockholm, Sweden In vivo Imaging of Immune Cell Interactions in Tumor Draining Lymph Nodes of SCCHN Stephan Lang, Essen, Germany
18:00	Scientific Get-together at the Posters Apéro with Wine, Cheese and Jazz

Thursday, 18. October 2018
08:15	Session 5: Microbiome Chair: Viktor Umansky, Heidelberg, Germany Title t.b.d. Philip Rosenstiel, Kiel, Germany The role of the gut microbiome in chronic diseases Matthias Laudes, Kiel, Germany Tumor and host factors regulating anti-tumor immunity and immotherpy efficacy Thomas F. Gajewski, Chicago, USA
09:30	Coffee break / Industrial Exhibtion / Poster
10:00	Session 6: Resistance/Immunosuppression Chairs: Barbara Wollenberg, Lübeck, Germany \| Thomas F. Gajewski, Chicago, USA PD1+X: early clinical trials with novel immunotherapy combinations Ulrich Keilholz, Berlin, Germany MDSC as a new target for cancer immunotherapy Viktor Umansky, Heidelberg, Germany Neo-adjuvant checkpoint inhibition – the pathway towards personalized immunotherapy Christian Blank, Amsterdam, Netherlands Interference between tumor mutational burden, HPV status, immune signatures and outcome in patients with head and neck cancer treated with chemoradiotherapy Ingeborg Tinhofer-Keilholz, Berlin, Germany
11:30	Posters of the day Chair: Ralph Pries, Lübeck, Germany Combining anti-VEGF-A and anti-PD-L1 therapy prolongs overall survival in small cell lung carcinomas (P26) Lydia Meder, Cologne, Germany Pre- and intratherapeutic cellular monitoring for dose adjustment of chemotherapy in aggressive lymphoma (P25) Julia Schröder, Brandenburg, Germany Killing melanoma cells with ROS provides immuno-protection against tumor growth in vivo (P24) Sander Bekeschus, Greifswald, Germany
12:00	Industry Symposium with Snack Bristol-Myers Squibb GmbH & Co KG aA From a clinical perspective: New developments in immuno-oncology – therapy, biomarkers and pipeline Angela Krackhardt, Munich, Germany Barbara Wollenberg, Lübeck, Germany
13:00	Postersession All presenters are asked to be present at their poster.
13:30	Session 7: Combinational strategies Chairs: Barbara Seliger, Halle, Germany \| Thomas Blankenstein, Berlin, Germany Dynamics of Conversation: Immunotherapy meets Tumor Microenvironment Iris Helfrich, Essen, Germany Development of personalized treatment and novel monitoring approaches for T-cell based immunotherapies in cancer Angela Krackhardt, München, Germany Modulating the tumor microenvironment Dirk Jäger, Heidelberg, Germany Priming anti-tumor immunity by radiotherapy Kirsten Lauber, München, Germany
15:00	Coffee break / Industrial Exhibtion
15:30	Session 8: New targets II Chairs: Angela Krackhardt, München, Germany \| Iris Helfrich, Essen, Germany Revision of immune escape mechanisms as novel therapeutic strategy Barbara Seliger, Halle, Germany T cell receptor gene therapy Thomas Blankenstein, Berlin, Germany Myeloid cells as biomarkers and therapeutic targets for cancer patients. Licia Rivoltini, Mailand, Italy
17:00	Wrap-up & Farewell

List of Posters

All presenters are asked to be present at their poster during the poster sessions.

(I) Immunomodulation / Tumor Biology
P01	Phenotype compartments and spatial distribution of clonally expanded T cells and their target antigens in rectal cancer Livius Penter, Berlin, Germany
P02	Integrin β4 synergizes with E-and P-selectin to regulate tumor growth: Unravelling the molecular mechanisms Sandra Hanika, Hamburg, Germany
P03	Immune suppression in sentinel lymph nodes draining HPV-negative head and neck cancer Rieneke van de Ven, Amsterdam, Netherlands
P04	Primary and recurrent head and neck squamous carcinomas are strikingly different regarding their immune microenvironment Christian Watermann, Lübeck, Germany
P05	The role of NFATc1 in T cell-mediated immune responses during the development of lung cancer Lisanne Heim, Erlangen, Germany
P06	Role of glycolysis for intestinal inflammation and carcinogenesis Felix Sommer, Kiel, Germany
P07	Epithelial RNase H2 Maintains Genome Integrity and Prevents Intestinal Tumorigenesis in Mice Konrad Aden, Kiel
P08	MALDI-imaging: Identification of protein signatures of genomic instability in colorectal cancers Timo Gemoll, Lübeck, Germany
P09	Investigating a potential role of Got1 in T cell exhaustion. Nina Weißhaar, Heidelberg, Germany

(II) New Targets
P10	Biparatopic heavy chain antibodies (bi-hcAbs): fusion of two distinct CD38-specific nanobodies into a human IgG1 bi-hcAb results in potent CDC vs. myeloma cells Julia Hambach and Katharina Petry, Hamburg, Germany
P11	Activation of MDA5 improves anti-tumor therapy and reduces suppressive capacity of myeloid-derived suppressor cells Philipp Metzger, Munich, Germany
P12	Effect of both PD-1/PD-L1 and ERK inhibitor on Cisplatin-sensitive (HEY) and Cisplatin-resistant (HEY-Cis) ovarian cancer cell lines Karen Bräutigam, Lübeck, Germany
P13	Effect of both PD-1/PD-L1 and ERK inhibitor on triple negative breast cancer cell lines and the non-triple negative cell line MCF-7 Karen Bräutigam, Lübeck, Germany
P14	Regulatory T cells in endogenous mouse lymphoma are antigen-specific nTregs and provide a target for immune checkpoint-inhibiting therapies Vera Bauer, München, Germany
P15	Specific Targeting of Oncogenic Mutations Using CRISPR-Technology to Destroy Activated Oncogenes and Enhance Immune Response Felix Oppel, Bochum, Germany

All presenters are asked to be present at their poster during the poster sessions.

(III) Therapy prognosis / prediction
P16	Effects of EGFR-MEK-ERK pathway on PD-L1 expression in head and neck squamous cell carcinoma Jochen Hess, Heidelberg, Germany
P17	The emerging role of extracellular vesicles in clinical research inflammation, cancer progression, metastasis Fanny Ender, Luebeck, Germany
P18	Identification, characterization and validation of neoantigens and neoantigen-reactive T cells in their distinct tumor microenvironment of patients included in the ImmuNEO MASTER pan-cancer cohort Celina Schwencke-Westphal, Munich, Germany
P19	CD8+ T cell response to HPV16 E7 predicts survival outcome in oropharyngeal cancer Holger Sudhoff, Bielefeld, Germany

(IV) Therapeutic strategies / approaches
P20	Current status of radiotherapy/radiochemotherapy and immunotherapy combinations– a German survey Lukas Käsmann, Munich, Germany
P21	ACTIVATION OF IMMUNE RESPONSE IN REFRACTORY PATIENTS TO STANDARD TREATMENT Andrea Abbona, Cuneo, Italy
P22	Which adjuvants for tumor-antigen vaccination induce powerful non-sialylated IgG antibodies? Marc Ehlers, Luebeck, Germany
P23	Irradiation-induced cell death modalities and dying cell clearance: Relevance for tumor radiosensitivity, clonogenic survival, and the outcome of radiotherapy Nikko Brix, Munich, Germany
P24	Killing melanoma cells with ROS provides immuno-protection against tumor growth in vivo Sander Bekeschus, Greifswald, Germany
P25	Pre- and intratherapeutic cellular monitoring for dose adjustment of chemotherapy in aggressive lymphoma Julia Schröder, Brandenburg, Germany
P26	Combining anti-VEGF-A and anti-PD-L1 therapy prolongs overall survival in small cell lung carcinomas Lydia Meder, Cologne, Germany
P27	Robust GMP manufacturing process with IL-2 and a glycoprotein antibody cocktail generates highly active human NK cell batches for cancer immunotherapy Katharina Bröker, Brandenburg a. d. Havel, Germany
P28	Progression of head and neck cancer is associated with elevated neutrophil extracellular traps formation by circulating neutrophils Anna-Sophie Decker, Essen, Germany

Confirmed Speakers

Christian Blank, Amsterdam, Netherlands
Thomas Blankenstein, Berlin, Germany
Ezra Cohen, San Diego, USA
Lisa Derosa, Montreal, Canada
Bernardo S. Franklin, Bonn, Germany
Udo Gaipl, Erlangen, Germany
Thomas F. Gajewski, Chicago, USA
Frank Gieseler, Lübeck, Germany
Robert Haddad, Boston, USA
Iris Helfrich, Essen, Germany
Jochen Hess, Heidelberg, Germany
Dirk Jäger, Heidelberg, Germany
Dieter Kabelitz, Kiel, Germany
Ulrike Koehl, Leipzig, Germany
Frank Gieseler, Lübeck, Germany
Angela Krackhardt, München, Germany

Kirsten Lauber, München, Germany
Stephan Lang, Essen, Germany
Matthias Laudes, Kiel, Germany
Marco C. Merlano, Cuneo, Italy
Hans-Georg Rammensee, Tübingen, Germany
Licia Rivoltini, Mailand, Italy
Philip Rosenstiel, Kiel, Germany
Martina Seifert, Berlin, Germany
Tanguy Seiwert, Chicago, USA
Barbara Seliger, Halle, Germany
David Tamborero, Stockholm, Sweden
Eric Tartour, Paris, France
Ingeborg Tinhofer-Keilholz, Berlin, Germany
Viktor Umansky, Heidelberg, Germany
Therasa L. Whiteside, Pittsburgh, USA
Gunnar Wichmann, Leipzig, Germany